Resignation of statutory auditor
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asston Pharmaceuticals has informed BSE that its statutory auditor, M/s. Doshi Doshi & Co (Chartered Accountants, FRN: 153683W), has resigned with effect from January 28, 2026. The auditor was originally appointed on September 30, 2024 for a 5-year term, so this is a mid-term exit roughly 16 months into the tenure. The cited reason is the auditor's own preoccupation with other assignments, making it unable to devote adequate time to the company's audit. Importantly, the resigning auditor has stated there are no concerns regarding the company's management and no other material reasons for stepping down. The company's Audit Committee and Board will appoint a new statutory auditor in due course to fill the resulting casual vacancy.
The auditor has explicitly confirmed no management-related concerns, which reduces the risk of a negative read on governance. However, shareholders should watch for the timely appointment of a replacement auditor, as prolonged vacancies can create compliance and disclosure uncertainty. The BSE-listed stock may see only a muted reaction given the routine nature of the cited reason.